Various sources of experimental data support this hypothesis: IL-1β production increased after p65 activation, SN-50 reduced IL-1β to basal levels in AAP-treated cells and neuroblastoma treatment with similar amounts of IL-1β as those produced by AAP treatment, slightly but significantly reduced neuroblastoma viability through caspase 3 activation. The gene discussed is IL1B; the disease is neuroblastoma.